Table 2 Meta-analysis of IGFBP-3 expressions for esophageal cancer
From: The low IGFBP-3 level is associated with esophageal cancer patients: a meta-analysis
Groups | I 2 | P a (heterogeneity) | OR | Lower limit | Upper limit | P b (OR) | Begg’s test | Egger’s test |
|---|---|---|---|---|---|---|---|---|
Cancer risk | 38.8% | 0.179 | 2.342 | 1.655 | 3.313 | 0.000 | 0.734 | 0.434 |
3-year survival rate | 71.20% | 0.015 | 2.163* | 1.092 | 4.287 | 0.027 | 0.734 | 0.814 |
Age | 77.40% | 0.035 | 0.980 | 0.520 | 1.860 | 0.733 | 1.000 | – |
Gender | 4.70% | 0.306 | 1.250 | 0.630 | 2.480 | 0.548 | 1.000 | – |
Location | 0.00% | 0.962 | 1.145 | 0.568 | 2.307 | 0.705 | 1.000 | – |
Tumor size | 72.40% | 0.057 | 1.650 | 0.900 | 3.010 | 0.536 | 1.000 | – |
T category | 19.60% | 0.265 | 2.870 | 1.510 | 5.450 | 0.005 | 1.000 | – |
N category | 0.00% | 0.863 | 3.211 | 1.561 | 6.607 | 0.002 | 1.000 | – |
M category | 0.00% | 0.380 | 3.270 | 1.670 | 6.400 | 0.001 | 1.000 | – |
TNM stage | 0.00% | 0.621 | 4.110 | 1.850 | 9.160 | 0.000 | 1.000 | – |
Survival status | 0.00% | 0.861 | 4.490 | 2.207 | 9.093 | 0.000 | 1.000 | – |